NBP insider transaction filings
NovaBridge Biosciences — 15 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-21. Screen NBP transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 11 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 4 legs across 4 filings by 3 insiders — 123,954 shares, $92,317 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 21.
- Largest priced transaction: sale of 107,978 shares @ $0.74 ($79,904) by Cao Sean Wuxiong, filed 2026-09-11.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Cao Sean Wuxiong — Chief Bus. Development Officer | 3 | — | 1 leg · 107,978 sh · $79,904 | 6 |
| Xu Cong Claire — EVP, Clinical Development | 2 | — | 2 legs · 7,767 sh · $6,584 | 4 |
| Dennis Phillip Andrew — Chief Medical Officer | 1 | — | 1 leg · 8,209 sh · $5,828 | 2 |
| Fu Wei — Director | 1 | — | — | 4 |
| Lenz Robert A. — Director | 1 | — | — | 2 |
| Gupta Srishti — Chief Executive Officer, Director | 1 | — | — | 1 |
| Hagler Mark Arnold — Chief Commercial Officer | 1 | — | — | 1 |
| Lin Liwei Lorraine — General Counsel | 1 | — | — | 1 |
Recent Form 4 filings — NovaBridge Biosciences
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-21 | 4 | Dennis Phillip Andrew — Chief Medical Officer | Option exercise (M): 23,695 · Sale (S): 8,209 @ $0.71 · Option exercise (M): 10,302 (derivative) @ $0 | EDGAR |
| 2026-09-11 | 4 | Cao Sean Wuxiong — Chief Bus. Development Officer | Sale (S): 107,978 @ $0.74 | EDGAR |
| 2026-09-08 | 4 | Cao Sean Wuxiong — Chief Bus. Development Officer | Option exercise (M): 235,136 · Option exercise (M): 104,236 · Option exercise (M): 102,233 (derivative) @ $0 · Option exercise (M): 45,320 (derivative) @ $0 | EDGAR |
| 2026-09-01 | 4 | Xu Cong Claire — EVP, Clinical Development | Option exercise (M): 9,382 · Sale (S): 3,282 @ $0.79 · Option exercise (M): 4,079 (derivative) @ $0 | EDGAR |
| 2026-08-25 | 4 | Lenz Robert A. — Director | Option exercise (M): 17,218 · Option exercise (M): 7,486 (derivative) @ $0 | EDGAR |
| 2026-07-10 | 4 | Hagler Mark Arnold — Chief Commercial Officer | Grant/award (A): 949,050 (derivative) @ $0 | EDGAR |
| 2026-07-10 | 4 | Lin Liwei Lorraine — General Counsel | Grant/award (A): 254,780 (derivative) @ $0 | EDGAR |
| 2026-07-08 | 4 | Gupta Srishti — Chief Executive Officer, Director | Grant/award (A): 3,000,000 (derivative) @ $0 | EDGAR |
| 2026-07-07 | 4 | Xu Cong Claire — SVP, Clinical Development | Option exercise (M): 12,432 · Sale (S): 4,485 @ $0.89 · Option exercise (M): 5,405 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Fu Wei — Director | Grant/award (A): 725,140 (derivative) @ $0 · Grant/award (A): 1,087,720 (derivative) @ $0 · Grant/award (A): 1,087,720 (derivative) @ $0 · Grant/award (A): 1,010,100 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Cao Sean Wuxiong — Chief Bus. Development Officer, Director | Grant/award (A): 181,280 (derivative) @ $0 · Grant/award (A): 181,290 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Dennis Phillip Andrew — Chief Medical Officer | Option exercise (M): 23,695 · Sale (S): 8,494 @ $0.66 · Option exercise (M): 10,302 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Xu Cong Claire — SVP, Clinical Development | Option exercise (M): 9,382 · Sale (S): 3,494 @ $3.94 · Option exercise (M): 4,079 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Cao Sean Wuxiong — See Remarks, Director | Sale (S): 21,399 @ $1.99 | EDGAR |
| 2026-04-28 | 4 | Hagler Mark Arnold — See Remarks | Purchase (P): 230,000 @ $2.51 | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=NBP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →